格隆汇1月7日|美国生物技术公司艾伯维下调2024财年调整后的每股盈利预测,由原先的10.9-10.94美元降至10.02-10.06美元,不及市场平均预期的10.94美元,因里程碑付款以及研究与开发成本相关的费用达到16亿美元。艾伯维预计第四季调整后每股盈利介乎2.06-2.1美元,去年同期为2.79美元。公司计划于1月31日公布第四季业绩。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.